ArticleRadiology case reports2025
Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab.
Article in Radiology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two basic criteria must be met for the diagnosis of extrapulmonary small cell carcinoma (EPSCC): the tumor must present histological characteristics of small cell carcinoma and a primary small cell lung carcinoma must be ruled out. We present the case of a 52-year-old woman who presented 8 months prior to consultation with an increase in abdominal circumference, epigastric pain and early satiety. Abdominal MRI showed an enlarged liver secondary to a mass affecting segments IV, V, VI, VII and VIII of 16.9 × 9.4 cm. Biopsy of the liver lesion was performed: small, round, blue cell neoplasm; immunohistochemistry revealed positivity for CKA1/A3, chromogranin, synaptophysin, CD56 and TTF-1. The diagnosis of EPSCC of the liver was made. It was decided to start systemic chemotherapy treatment with carboplatin, etoposide and durvalumab with clinical improvement of the symptoms. The patient died 10 months after starting chemoimmunotherapy treatment. Optimal treatment of EPSCC is generally extrapolated from small lung cell cancer. There is insufficient evidence to routinely recommend the use of immunotherapy in this group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.